Please assess the completion status of the following clinical trial:

Trial Title: Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified NSCLC~* Not eligible for Radiochemotherapy or patient refuses chemotherapy~* FeV1 \>1.5 L or min. 50%~* KPI \>= 70%~* Life expectancy \> 6 months~* Weight loss less than 10% of body weight in 12 months~* Compliance~* Adequate blood counts (LC \> 3000 x 10\^3/ml, Tc \>100000 x 10\^3/ml, Hb \> 10 g/dl)~* Effective contraception~Amendment 1/07: FeV1 \>1.2 L or min 40%~Exclusion Criteria:~* Active infection~* Reduced liver function~* Vena cava superior syndrome~* Malignant pleural effusion~* Pregnancy or breast feeding~* Additional serious systemic disease~* Secondary malignancy (except carcinoma in situ of the cervix, basalioma of the skin, secondary cancer in remission for \> 5 years)~* Known allergies against proteins~* History of former antibody therapy~* Allergy against i.v. contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).